Table 1.
Characteristics of HCC
| Insurance | No | 53 | 32.92% |
| Yes | 108 | 67.08% | |
| Age | Median (IQR) | 59 (9.25) | |
| Sex | Female | 24 | 14.91% |
| Male | 137 | 85.09% | |
| Ethnicity | African American | 24 | 15.38% |
| Asian | 5 | 3.21% | |
| Hispanic | 73 | 46.79% | |
| Native American | 6 | 3.85% | |
| White | 48 | 30.77% | |
| BMI | Median (IQR) | 27.27 (6.89) | |
| Surveillance | No | 86 | 53.42% |
| Yes | 75 | 46.58% | |
| Initial MELD | Median (IQR) | 11 (7.25) | |
| Final MELD | Median (IQR) | 16 (11) | |
| Liver Biopsy | No | 104 | 64.60% |
| Yes | 57 | 35.40% | |
| Milan criteria | No | 93 | 57.76% |
| Yes | 68 | 42.24% | |
| Transplant referral | No | 106 | 69.28% |
| Yes | 47 | 30.72% | |
| Listed for Transplant | No | 148 | 94.87% |
| Yes | 8 | 5.13% | |
| Treatment for HCC | No | 64 | 39.75% |
| Yes | 97 | 60.25% | |
| IR RFA | No | 122 | 75.78% |
| Yes | 39 | 24.22% | |
| IR TACE | No | 110 | 68.32% |
| Yes | 51 | 31.68% | |
| Sorafenib | No | 146 | 90.68% |
| Yes | 15 | 9.32% | |
| Surgical RFA | No | 156 | 96.89% |
| Yes | 5 | 3.11% | |
| Surgical Resection | No | 151 | 94.38% |
| Yes | 9 | 5.63% | |
| Survival | Dead | 92 | 57.50% |
| Alive | 68 | 42.50% | |
| Hospice care | No | 79 | 53.74% |
| Yes | 68 | 46.26% | |
Abbreviations: BMI, body mass index; HCC, hepatocellular carcinoma; IQR, interquartile range; MELD, Model for End Stage Liver Disease; RFA, radiofrequency ablation; TACE, transarterial chemoembolization.